This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Hikma reaches settlement in US pay-for-delay litigation over Xyrem drug

( May 7, 2025, 16:00 GMT | Official Statement) -- MLex Summary: Class plaintiffs requested a US judge to preliminary approve a settlement with Hikma, the last defendant in litigation that accused pharmaceutical companies of engaging in an anticompetitive scheme to delay entry of a generic version of narcolepsy drug Xyrem. In a motion for preliminary approval of the class-action settlement with Hikma, the class plaintiffs said the settlement "provides for a cash settlement fund totaling $50,000,000.00, which is in addition to the proposed cash settlement with Jazz [Pharmaceuticals] that is presently before this Court pending preliminary approval, and is set to be heard on May 15." Motion for preliminary approval attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections